{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:01:15Z","timestamp":1789524075486,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Arab Journal of Gastroenterology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ajg.2026.02.001","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T12:36:55Z","timestamp":1773664615000},"page":"155-159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Beyond viral elimination: the emerging epidemic of metabolic dysfunction-associated steatotic liver disease (MASLD)\u2013viral hepatitis overlap"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9528-2674","authenticated-orcid":false,"given":"Rahma","family":"Mohamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6175-1690","authenticated-orcid":false,"given":"Aya M.","family":"Abdelmagid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6155-2819","authenticated-orcid":false,"given":"Amani M.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3791-5998","authenticated-orcid":false,"given":"Ahmed M.","family":"Kamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3485-1183","authenticated-orcid":false,"given":"Ahmed","family":"Cordie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajg.2026.02.001_b0005","unstructured":"World Health Organization. (2023, October 9). WHO commends Egypt for its progress on the path to eliminate hepatitis C. https:\/\/www.who.int\/news\/item\/09-10-2023-who-commends-egypt-for-its-progress-on-the-path-to-eliminate-hepatitis-c (accessed 17 October 2025)."},{"key":"10.1016\/j.ajg.2026.02.001_b0010","unstructured":"World Health Organization Regional Office for the Eastern Mediterranean. (2025, May 1). Egypt becomes the first country in the Region to achieve hepatitis B control status. https:\/\/www.emro.who.int\/egy\/egypt-news\/egypt-becomes-the-first-country-in-the-region-to-achieve-hepatitis-b-control-status.html (accessed 17 October 2025)."},{"key":"10.1016\/j.ajg.2026.02.001_b0015","doi-asserted-by":"crossref","unstructured":"Tacke F, Horn P, Wai-Sun Wong V, Ratziu V, Bugianesi E, Francque S, et al. EASL\u2013EASD\u2013EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol [Internet]. 2024;81(3):492\u2013542. Available from: https:\/\/doi.org\/10.1016\/j.jhep.2024.04.031.","DOI":"10.1016\/j.jhep.2024.04.031"},{"issue":"9","key":"10.1016\/j.ajg.2026.02.001_b0020","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1210\/clinem\/dgac321","article-title":"Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: a meta-analysis and systematic review of 10 739 607 individuals","volume":"107","author":"Chan","year":"2022","journal-title":"J Clin Endocrinol Metabol"},{"issue":"6","key":"10.1016\/j.ajg.2026.02.001_b0025","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.cgh.2024.01.045","article-title":"Chronic Viral Hepatitis B and C Outweigh MASLD in the Associated risk of Cirrhosis and HCC","volume":"22","author":"Lee","year":"2024","journal-title":"Clin Gastroenterol Hepatol [Internet]"},{"issue":"4","key":"10.1016\/j.ajg.2026.02.001_b0030","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S2468-1253(22)00386-7","article-title":"Global reporting of progress towards elimination of hepatitis B and hepatitis C","volume":"8","author":"Cui","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"23","key":"10.1016\/j.ajg.2026.02.001_b0035","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.21037\/atm-21-3052","article-title":"Concurrence and impact of hepatic steatosis on chronic hepatitis B patients: a systematic review and meta-analysis","volume":"9","author":"Jiang","year":"2021","journal-title":"Ann Translat Med"},{"issue":"6","key":"10.1016\/j.ajg.2026.02.001_b0040","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.3390\/clinpract14060200","article-title":"Metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C virus infection: from basics to clinical and nutritional management","volume":"14","author":"Gonzalez-Aldaco","year":"2024","journal-title":"Clinics and Practice"},{"issue":"4","key":"10.1016\/j.ajg.2026.02.001_b0045","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jhep.2021.05.022","article-title":"Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: Data from Global Burden of Disease 2009-2019","volume":"75","author":"Golabi","year":"2021","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.ajg.2026.02.001_b0050","doi-asserted-by":"crossref","first-page":"211","DOI":"10.4103\/sjg.SJG_122_18","article-title":"Nonalcoholic fatty liver disease burden\u2013Saudi Arabia and United Arab Emirates, 2017\u20132030","volume":"24","author":"Alswat","year":"2018","journal-title":"Saudi J Gastroenterol"},{"key":"10.1016\/j.ajg.2026.02.001_b0055","series-title":"Metabolic syndrome","first-page":"1","article-title":"Obesity in middle east","author":"Nikoloski","year":"2015"},{"issue":"1","key":"10.1016\/j.ajg.2026.02.001_b0060","doi-asserted-by":"crossref","first-page":"66","DOI":"10.14218\/JCTH.2015.00051","article-title":"Hepatitis C virus, insulin resistance, and steatosis","volume":"4","author":"Kralj","year":"2016","journal-title":"J Clin Transl Hepatol"},{"issue":"11","key":"10.1016\/j.ajg.2026.02.001_b0065","doi-asserted-by":"crossref","first-page":"e01239","DOI":"10.1128\/jvi.01239-24","article-title":"Small hepatitis B virus surface antigen (SHBs) induces dyslipidemia by suppressing apolipoprotein-AII expression through ER stress-mediated modulation of HNF4\u03b1 and C\/EBP\u03b3","volume":"98","author":"Wu","year":"2024","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.ajg.2026.02.001_b0070","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.tem.2015.11.008","article-title":"The role of cholesterol in the pathogenesis of NASH","volume":"27","author":"Ioannou","year":"2016","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ajg.2026.02.001_b0075","doi-asserted-by":"crossref","first-page":"52","DOI":"10.4239\/wjd.v5.i1.52","article-title":"Hepatitis C virus infection and insulin resistance","volume":"5","author":"Bose","year":"2014","journal-title":"World J Diabetes"},{"issue":"36","key":"10.1016\/j.ajg.2026.02.001_b0080","doi-asserted-by":"crossref","first-page":"8161","DOI":"10.3748\/wjg.v22.i36.8161","article-title":"Impact of hepatitis B virus infection on hepatic metabolic signaling pathway","volume":"22","author":"Shi","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.ajg.2026.02.001_b0085","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12944-024-02108-x","article-title":"Updated mechanisms of MASLD pathogenesis","volume":"23","author":"Li","year":"2024","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.ajg.2026.02.001_b0090","doi-asserted-by":"crossref","unstructured":"Lin, Y. J., Shaw, T. W. G., Yang, H. I., Lu, S. N., Jen, C. L., Wang, L. Y., ... & REVEAL\u2010HCV Study Group. (2017). Chronic hepatitis C virus infection and the risk for diabetes: a community\u2010based prospective study. Liver International, 37(2), 179-186.","DOI":"10.1111\/liv.13194"},{"issue":"11\u201312","key":"10.1016\/j.ajg.2026.02.001_b0095","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/apt.17233","article-title":"Prevalence and clinical characteristics of patients with metabolic dysfunction\u2010associated fatty liver disease with hepatitis C virus infection\u2014a population\u2010based study","volume":"56","author":"Attia","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.ajg.2026.02.001_b0100","doi-asserted-by":"crossref","DOI":"10.1111\/jvh.70004","article-title":"Association of MASLD phenotypes with liver fibrosis in hepatitis C: the role of cardiometabolic risk factors","volume":"32","author":"Elgretli","year":"2025","journal-title":"J Viral Hepat"},{"issue":"1","key":"10.1016\/j.ajg.2026.02.001_b0105","first-page":"128","article-title":"Metabolic dysfunction-associated fatty liver disease (MAFLD) and viral hepatitis","volume":"10","author":"Wang","year":"2021","journal-title":"J Clin Transl Hepatol"},{"issue":"10","key":"10.1016\/j.ajg.2026.02.001_b0110","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/apt.16346","article-title":"MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective","volume":"53","author":"Fouad","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.ajg.2026.02.001_b0115","first-page":"547","article-title":"HIV and liver disease: a comprehensive update","volume":"30","author":"Sherman","year":"2022","journal-title":"Topics Antiviral Med"},{"key":"10.1016\/j.ajg.2026.02.001_b0120","unstructured":"You H, Wang F, Li T, Xu X, Sun Y, Nan Y, et al. Guidelines for the Prevention and Treatment of Chronic Hepatitis B (version 2022) . J Clin Transl Hepatol. 11(6):1425\u201342."},{"issue":"6","key":"10.1016\/j.ajg.2026.02.001_b0125","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1159\/000525518","article-title":"Hepatitis B virus treatment and hepatocellular carcinoma: controversies and approaches to consensus","volume":"11","author":"Kim","year":"2022","journal-title":"Liver cancer"},{"issue":"4","key":"10.1016\/j.ajg.2026.02.001_b0130","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ajg.2026.02.001_b0135","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2024.1347459","article-title":"Metabolic dysfunction-associated steatotic liver disease increases hepatocellular carcinoma risk in chronic hepatitis B patients: a retrospective cohort study","volume":"15","author":"Lin","year":"2024","journal-title":"Front Physiol"},{"issue":"3","key":"10.1016\/j.ajg.2026.02.001_b0140","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/jgh.13536","article-title":"Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B","volume":"32","author":"Chan","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.ajg.2026.02.001_b0145","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1053\/j.gastro.2018.08.024","article-title":"Risk of Hepatocellular Cancer in patients with Non-Alcoholic Fatty Liver Disease","volume":"155","author":"Kanwal","year":"2018","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.ajg.2026.02.001_b0150","first-page":"1061","article-title":"Prevalence of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa","volume":"44","author":"Younossi","year":"2024","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"issue":"2","key":"10.1016\/j.ajg.2026.02.001_b0155","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1093\/infdis\/jiaa739","article-title":"Association between Fatty Liver and Cirrhosis, Hepatocellular Carcinoma, and Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B","volume":"224","author":"Li","year":"2020","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.ajg.2026.02.001_b0160","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s12072-021-10218-2","article-title":"Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection","volume":"15","author":"Mak","year":"2021","journal-title":"Hep Intl"},{"key":"10.1016\/j.ajg.2026.02.001_b0165","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.965548","article-title":"NAFLD and HBV interplay - related mechanisms underlying liver disease progression","volume":"13","author":"Tourkochristou","year":"2022","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.ajg.2026.02.001_b0170","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/ijc.26165","article-title":"Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies","volume":"130","author":"Wang","year":"2012","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.ajg.2026.02.001_b0175","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","article-title":"EASL Clinical Practice guidelines on the management of hepatitis B virus infection","volume":"83","author":"Cornberg","year":"2025","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.ajg.2026.02.001_b0180","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1111\/apt.17953","article-title":"Poor accuracy and sustainability of the first-step FIB4 EASL pathway for stratifying steatotic liver disease risk in the general population","volume":"59","author":"De Vincentis","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.ajg.2026.02.001_b0185","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jhep.2020.10.016","article-title":"HCC surveillance after SVR in patients with F3\/F4 fibrosis","volume":"74","author":"Ioannou","year":"2021","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.ajg.2026.02.001_b0190","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/flgastro-2021-102064","article-title":"EASL clinical practice guidelines: non-invasive liver tests for evaluation of liver disease severity and prognosis","volume":"13","author":"Archer","year":"2022","journal-title":"Frontline Gastroenterol"},{"issue":"4","key":"10.1016\/j.ajg.2026.02.001_b0195","first-page":"1006","article-title":"Which form of Tenofovir Should Be used Worldwide: Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide?","volume":"79","author":"Hill","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ajg.2026.02.001_b0200","unstructured":"World Health Organization (WHO). Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. 2024."},{"issue":"10","key":"10.1016\/j.ajg.2026.02.001_b0205","doi-asserted-by":"crossref","first-page":"e640","DOI":"10.1016\/S2352-3018(23)00151-0","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3","volume":"10","author":"Avihingsanon","year":"2023","journal-title":"lancet HIV"},{"issue":"1","key":"10.1016\/j.ajg.2026.02.001_b0210","doi-asserted-by":"crossref","first-page":"27369","DOI":"10.1038\/s41598-024-78656-0","article-title":"Comparison of lipid profile alterations in chronic hepatitis b patients receiving tenofovir alafenamide or tenofovir disoproxil fumarate","volume":"14","author":"Lin","year":"2024","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.ajg.2026.02.001_b0215","doi-asserted-by":"crossref","first-page":"e652","DOI":"10.1093\/cid\/ciac621","article-title":"Metabolic-related outcomes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in adults with human immunodeficiency virus (HIV): a multicenter prospective cohort study","volume":"76","author":"Mart\u00ednez-Sanz","year":"2023","journal-title":"Clin Infect Dis an Off Publ Infect Dis Soc Am"},{"issue":"10","key":"10.1016\/j.ajg.2026.02.001_b0220","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1016\/S2352-3018(24)00183-8","article-title":"Changes in bodyweight after initiating antiretroviral therapy close to HIV-1 seroconversion: an international cohort collaboration","volume":"11","author":"Pantazis","year":"2024","journal-title":"Lancet HIV"},{"issue":"9","key":"10.1016\/j.ajg.2026.02.001_b0225","doi-asserted-by":"crossref","first-page":"e2332968","DOI":"10.1001\/jamanetworkopen.2023.32968","article-title":"Use of tenofovir alafenamide fumarate for HIV pre-exposure prophylaxis and incidence of hypertension and initiation of statins","volume":"6","author":"Rivera","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"9","key":"10.1016\/j.ajg.2026.02.001_b0230","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1097\/QAD.0000000000003903","article-title":"The effect of weight gain and metabolic dysfunction-associated steatotic liver disease on liver fibrosis progression and regression in people with HIV","volume":"38","author":"Guaraldi","year":"2024","journal-title":"AIDS"},{"issue":"10","key":"10.1016\/j.ajg.2026.02.001_b0235","article-title":"Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B","volume":"5","author":"Lim","year":"2023","journal-title":"JHEP reports Innov Hepatol"},{"issue":"2","key":"10.1016\/j.ajg.2026.02.001_b0240","article-title":"Lower incidence of hepatocellular carcinoma with tenofovir alafenamide in chronic hepatitis B: evidence from a large-scale cohort","volume":"7","author":"Yoo","year":"2025","journal-title":"JHEP reports Innov Hepatol"},{"issue":"6","key":"10.1016\/j.ajg.2026.02.001_b0245","doi-asserted-by":"crossref","DOI":"10.3390\/life14060742","article-title":"Metabolic dysfunction-associated steatotic liver disease in people living with HIV\u2014limitations on antiretroviral therapy selection","volume":"14","author":"Kalopitas","year":"2024","journal-title":"Life"},{"issue":"4","key":"10.1016\/j.ajg.2026.02.001_b0250","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","article-title":"96\u00a0weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection","volume":"68","author":"Agarwal","year":"2018","journal-title":"J Hepatol"}],"container-title":["Arab Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1687197926000298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1687197926000298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T07:28:37Z","timestamp":1779866917000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1687197926000298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1687197926000298"],"URL":"https:\/\/doi.org\/10.1016\/j.ajg.2026.02.001","relation":{},"ISSN":["1687-1979"],"issn-type":[{"value":"1687-1979","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond viral elimination: the emerging epidemic of metabolic dysfunction-associated steatotic liver disease (MASLD)\u2013viral hepatitis overlap","name":"articletitle","label":"Article Title"},{"value":"Arab Journal of Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajg.2026.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Pan-Arab Association of Gastroenterology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}